Skip to main content
. 2022 May 19;12:8355. doi: 10.1038/s41598-022-12395-y

Table 2.

Unadjusted and adjusted logistic regression models for the likelihood of SARS-CoV-2 test-positivity compared to non-positive (negative and not tested) and test-negative pregnant women in Norway, in relation to characteristics.

Characteristics Test-positive
n = 929¤
Non-positive
n = 80,658
Test-negative
n = 29,699
Test-positive vs. non-positive Test-positive vs. test-negative
Unadjusted model Adjusted for age, birth region and education* Unadjusted model Adjusted for age, birth region and education*
n (%) n (%) n (%) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Background
Age (years)
 < 25 71 (7.6) 6362 (7.9) 1948 (6.6) 0.94 (0.73–1.22) 0.76 (0.58–0.99) 1.20 (0.92–1.55) 0.82 (0.63–1.08)
 25–29 277 (29.8) 24,407 (30.3) 8628 (29.1) 0.96 (0.82–1.12) 0.93 (0.80–1.09) 1.06 (0.90–1.23) 0.98 (0.83–1.15)
 30–34 378 (40.7) 31,980 (39.7) 12,430 (41.9) Reference Reference Reference Reference
 ≥ 35 203 (21.9) 17,909 (22.2) 6693 (22.5) 0.96 (0.81–1.14) 0.86 (0.72–1.02) 1.00 (0.84–1.19) 0.85 (0.72–1.02)
Parity
 0 329 (35.4) 34,081 (42.3) 11,407 (38.4) Reference Reference Reference Reference
 1 340 (36.6) 30,690 (38.1) 12,597 (42.4) 1.15 (0.99–1.33) 1.13 (0.96–1.32) 0.94 (0.80–1.09) 0.97 (0.83–1.14)
 2 166 (17.3) 11,548 (14.3) 4347 (14.6) 1.44 (1.19–1.75) 1.27 (1.04–1.55) 1.28 (1.06–1.56) 1.16 (0.95–1.43)
 ≥ 3 99 (10.7) 4339 (5.4) 1348 (4.5) 2.36 (1.88–2.97) 1.46 (1.13–1.88) 2.54 (2.01–3.21) 1.43 (1.10–1.88)
BMI
 < 18.5 23 (2.7) 2448 (3.3) 811 (2.9) 0.87 (0.57–1.32) 0.72 (0.47–1.10) 0.98 (0.64–1.49) 0.76 (0.49–1.17)
 18.5–< 25 472 (55.3) 43,848 (58.6) 16,256 (58.9) Reference Reference Reference Reference
 25–< 30 232 (27.2) 17,800 (23.8) 6543 (23.7) 1.21 (1.03–1.42) 1.12 (0.95–1.31) 1.22 (1.04–1.43) 1.09 (0.93–1.29)
 30–< 35 90 (10.5) 7145 (9.6) 2629 (9.5) 1.17 (0.93–1.47) 1.09 (0.86–1.37) 1.18 (0.94–1.48) 1.03 (0.61–1.22)
 ≥ 35 37 (4.3) 3557 (4.8) 1343 (4.9) 0.97 (0.69–1.35) 0.95 (0.68–1.34) 0.95 (0.68–1.33) 0.86 (0.83–1.38)
 Missing 75 5860 2117
Educational level (years)
 ≤ 9 188 (24.6) 10,580 (14.4) 3217 (11.5) 2.12 (1.78–2.53) 1.41 (1.16–1.71) 2.86 (2.39–3.42) 1.73 (1.42–2.12)
 10–12 179 (23.4) 15,612 (21.1) 5243 (18.7) 1.37 (1.15–1.63) 1.29 (1.08–1.54) 1.67 (1.40–2.00) 1.52 (1.27–1.83)
 > 12) 398 (52.0) 47,494 (64.4) 19,505 (69.7) Reference Reference Reference Reference
 Missing 164 6972 1734
Birth region
 Scandinavia# 461 (49.7) 60,185 (74.7) 23,867 (81.4) Reference Reference Reference Reference
 Other European c ountry 153 (16.5) 8883 (12.1) 2506 (8.4) 2.25 (1.87–2.70) 2.13 (1.75–2.60) 3.16 (2.62–3.81) 2.75 (2.25–3.36)
 Middle East/Africa 224 (24.1) 5454 (6.8) 1450 (4.9) 5.36 (4.56–6.30) 4.66 (2.86–5.63) 8.00 (6.76–9.47) 5.95 (4.90–7.23)
 Other 90 (9.8) 6047 (7.5) 1867 (6.3) 1.94 (1.55–2.44) 1.83 (1.45–2.32) 2.52 (2.01–3.18) 2.22 (1.75–2.82)
 Missing 1 89 0
Smoking status
 Smoker, yes 52 (6.3) 4175 (5.8) 1352 (5.1) 1.10 (0.83–1.46) 1.01 (0.76–1.35) 1.26 (0.95–1.68) 1.00 (0.74–1.34)
 Missing 106 8205 3090
Work situation
 Employed 527 (72.6) 58,156 (84.1) 22,378 (87.2) Reference Reference Reference Reference
 Unemployed 199 (27.4) 10,999 (15.9) 3274 (12.8) 2.00 (1.69–2.35) 1.16 (0.96–1.40) 2.58 (2.18–3.05) 1.30 (1.08–1.58)
 Missing 203 11,503 4047
 Co-habits with partner
 No 52 (5.7) 3213 (4.0) 1068 (3.7) 1.44 (1.09–1.91) 0.96 (0.72–1.28) 1.60 (1.20–2.13) 0.88 (0.65–1.19)
 Missing 21 1234 490
Pre-existing co-morbidities
Chronic hypertension 3 (0.3) 462 (0.6) 184 (0.6) 0.56 (0.18–1.75) 0.53 (0.17–1.66) 0.52 (0.17–1.63) 0.44 (0.14–1.40)
Diabetes 8 (0.9) 572 (0.7) 215 (0.7) 1.22 (0.60–2.45) 1.35 (0.62–2.54) 1.19 (0.59–2.42) 1.09 (0.53–2.26)
Lung disease/asthma 52 (5.6) 5142 (6.4) 2048 (6.9) 0.87 (0.66–1.15) 0.86 (0.51–1.46) 0.80 (0.60–1.06) 0.98 (0.73–1.30)
Chronic kidney disease 1 (0.1) 472 (0.6) 178 (0.6)
Cardiovascular disease 0 (–) 461 (0.6) 173 (0.6)
Prior thrombosis 0 (–) 166 (0.2) 56 (0.2)
Composite of the above 61 (6.6) 6982 (8.7) 2738 (9.2) 0.74 (0.57–0.96) 0.87 (0.67–1.14) 0.69 (0.53–0.90) 0.80 (0.62–1.05)
Pregnancy related factors
Multiple pregnancy 12 (1.3) 1071 (1.3) 427 (1.4) 0.97 (0.55–1.72) 0.97 (0.55–1.72) 0.90 (0.50–1.60) 0.88 (0.49–1.58)
Pre-eclampsia, HELLP and eclampsia 13 (1.4) 2215 (2.8) 842 (2.8) 0.50 (0.29–0.87) 0.54 (0.31–0.93) 0.49 (0.28–0.84) 0.50 (0.29–0.88)
Gestational diabetes 77 (8.3) 4758 (5.9) 1731 (5.8) 1.44 (1.14–1.82) 1.13 (0.89–1.43) 1.46 (1.15–1.85) 1.09 (0.85–1.39)
In vitro fertilization (IVF) 28 (3.0) 3819 (4.7) 1329 (4.5) 0.63 (0.43–0.91) 0.72 (0.49–1.06) 0.66 (0.45–0.97) 0.80 (0.54–1.17)

¤8 of 929 (0.9%) positive women had been vaccinated during the study period. *For the association between age and tested, the adjusted model included the covariate education and birth region. For the association between education and tested, the adjusted model included the covariates age and birth region. For the association between birth region and tested, the adjusted model included the covariates age and education. #Sweden, Norway, Denmark.